Table 2.
Univariate and multivariate cox regression analyses of prognostic factors in nasopharyngeal carcinoma
| Univariate analysis | Multivariate analysis | |||||
|---|---|---|---|---|---|---|
| Variable | HR | 95% CI | P-value* | HR | 95% CI | P-value* |
| Overall survival | ||||||
| Talin-1 expression (high vs. low) | 2.15 | 1.28-3.63 | 0.004 | 1.87 | 1.10-3.16 | 0.02 |
| TNM stage (III-IV vs. I-II) | 3.06 | 1.45-6.47 | 0.003 | 2.97 | 1.40-6.29 | 0.005 |
| Age (≥45 years vs. <45 years) | 1.63 | 0.96-2.78 | 0.07 | |||
| Sex (male vs. female) | 1.57 | 0.83-2.96 | 0.17 | |||
| WHO Type (III vs. I-II) | 0.63 | 0.20-2.03 | 0.44 | |||
| VCA-IgA (≥1:80 vs. < 1:80) | 1.50 | 0.64-3.49 | 0.35 | |||
| EA-IgA (≥1:10 vs. < 1:10) | 1.04 | 0.56-1.93 | 0.90 | |||
| Distant metastasis-free survival | ||||||
| Talin-1 expression (high vs. low) | 2.39 | 1.38-4.15 | 0.002 | 2.18 | 1.25-3.78 | 0.006 |
| TNM stage (III-IV vs. I-II) | 3.78 | 1.61-8.86 | 0.002 | 3.48 | 1.48-8.17 | 0.004 |
| Age (≥45 years vs. < 45 years) | 1.58 | 0.90-2.78 | 0.11 | |||
| Sex (male vs. female) | 1.51 | 0.77-2.94 | 0.23 | |||
| WHO Type (III vs. I-II) | 0.54 | 0.17-1.73 | 0.30 | |||
| VCA-IgA (≥1:80 vs. < 1:80) | 1.10 | 0.50-2.45 | 0.81 | |||
| EA-IgA (≥1:10 vs. < 1:10) | 1.30 | 0.65-2.60 | 0.45 | |||
Abbreviations: WHO: World Health Organization; VCA-IgA: viral capsid antigen immunoglobulin A; EA-IgA: early antigen immunoglobulin A. P-values* were calculated using univariate and multivariate cox regression analyses.